BAM
OCUL icon

Belpointe Asset Management’s Ocular Therapeutix OCUL Stock Holding History

Belpointe Asset Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,550
Closed -$66.1K – 2428
2023
Q1 		$66.1K Hold
12,550
– – ﹤0.01% 1553
2022
Q4 		$35.3K Buy
+12,550
New +$41.6K ﹤0.01% 1822

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Belpointe Asset Management's OCUL Position: Q2 2023 in Review

Belpointe Asset Management sold out of Ocular Therapeutix (OCUL) in Q2 2023, closing a stake of 12,550 shares — an estimated $66.1K sold.

Belpointe Asset Management first reported a position in OCUL in Q4 2022 and held it in 2 quarters. The position peaked at $66.1K in Q1 2023. 135 funds tracked by Wall St. Rank hold OCUL as of Q2 2023.

  • Belpointe Asset Management reported no remaining Ocular Therapeutix position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 12,550 Ocular Therapeutix shares in Q2 2023, an estimated $66.1K.
  • Belpointe Asset Management first reported a position in Ocular Therapeutix in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Ocular Therapeutix position peaked at $66.1K in Q1 2023.
  • 135 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.